Comparison of the TP53 Arg72Pro genotypes distribution between control and case cohorts shows the prevalence of Pro/Pro homozygous (13 versus 5%) and Arg/Pro heterozygous (43 versus 38%) among esophageal cancer patients. This evidence concerns the gene TP53 and esophageal cancer.